US Patent 7,125,879: Rilpivirine Claim Scope, Expiration, Orange Book Status, and Patent Landscape
US Patent 7,125,879 covers rilpivirine, also known as TMC278, including its E-isomer, salts, N-oxides, pharmaceutical compositions, tablets, HIV-treatment methods, and use against HIV-1 resistant to earlier non-nucleoside reverse transcriptase inhibitors. The core patent is expired based on its 20-year term, with the base expiration occurring in 2021. Its commercial importance was tied to Edurant, Complera, Odefsey, and Juluca. The patent remains relevant for historical validity analysis and freedom-to-operate review, but it no longer provides a current US exclusionary right unless a separate term extension or related patent applies.
What drug does US Patent 7,125,879 protect?
US Patent 7,125,879 protects rilpivirine and related chemical forms. Rilpivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor, or NNRTI, marketed primarily as rilpivirine hydrochloride.
The claimed active compound is:
4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
The compound is generally identified as rilpivirine, with the therapeutically relevant commercial form being rilpivirine hydrochloride. The patent was assigned to Tibotec Pharmaceuticals, later associated with Janssen Pharmaceuticals and Johnson & Johnson.
Key patent data
| Item |
Data |
| US patent |
7,125,879 |
| Title |
Diarylpyrimidines |
| Drug |
Rilpivirine, TMC278 |
| Therapeutic class |
NNRTI antiretroviral |
| Original developer |
Tibotec Pharmaceuticals |
| Commercial sponsor |
Janssen Pharmaceuticals |
| Patent grant date |
October 24, 2006 |
| Earliest relevant priority |
2000 |
| US filing/PCT chronology |
2001 national-stage period |
| Base patent-term expiration |
May 23, 2021 |
| Primary marketed salt |
Rilpivirine hydrochloride |
| Main US product |
Edurant |
| Related products |
Complera, Odefsey, Juluca |
The precise expiration date for a US patent is determined from the applicable US filing date, any patent-term adjustment, and any statutory extension. Public patent records identify the core term as expiring in 2021. FDA pediatric exclusivity, if attached to the listed product and patent, could have extended regulatory protection by six months, but it did not create a new long-term composition patent term.
What are the strongest claims in US Patent 7,125,879?
The strongest claims are the compound claims, particularly claims 1 and 2. These claims directly cover rilpivirine rather than only a formulation, indication, or manufacturing process.
Claims 1 and 2: core chemical protection
Claim 1 covers:
- The named diarylpyrimidine compound.
- N-oxides.
- Addition salts.
- Quaternary amines.
- Stereochemically isomeric forms.
Claim 2 separately claims the named compound itself. This provides a narrower compound claim directed to the neutral parent structure.
From an infringement perspective, a product containing rilpivirine hydrochloride would generally implicate claim 1 through the addition-salt language and claim 2 through the underlying active moiety, subject to claim construction and the treatment of the salt form.
Claim 1 is broader than claim 2 because it extends beyond the neutral parent compound. Its coverage includes chemical modifications that retain the claimed rilpivirine core or fall within the specified salt, N-oxide, quaternary-ammonium, or stereochemical categories.
Claims 3 and 4: structure-dependent claims
Claims 3 and 4 depend on structural drawings that are not reproduced in the supplied text. Their legal scope therefore turns on the exact structures shown in the patent figures.
They may represent specific stereochemical or geometric forms of the cyanoethenyl substituent, including E/Z configurations or closely related analogues. The written claim text alone does not support a complete claim construction for these claims.
The patent’s commercially important stereochemical form is the E-isomer of rilpivirine. Claims 6, 8, and 10 expressly distinguish the E form.
Claims 5 through 10: salts and N-oxides
These claims narrow the chemical coverage:
| Claims |
Subject matter |
| 5 |
Addition salt of rilpivirine |
| 6 |
Addition salt of E-rilpivirine |
| 7 |
Hydrochloride salt of rilpivirine |
| 8 |
Hydrochloride salt of E-rilpivirine |
| 9 |
N-oxide of rilpivirine |
| 10 |
N-oxide of E-rilpivirine |
Claim 8 is particularly relevant to the commercial product because rilpivirine is administered as the hydrochloride salt. A claim directed specifically to the E-isomer hydrochloride has narrower literal scope than claim 1 but is commercially significant because the marketed active form is the E-isomer.
What pharmaceutical compositions and tablet formulations are protected?
Claims 11 through 18 cover pharmaceutical compositions and tablet dosage forms containing a claimed rilpivirine compound.
Composition and manufacturing claims
Claim 11 covers a pharmaceutical composition containing:
- A pharmaceutically acceptable carrier; and
- An effective amount of a compound identified through the specified dependency chain.
Claim 12 covers the process of preparing that composition by mixing the active compound with a pharmaceutically acceptable carrier.
These claims are narrower than the core compound claims. They require a pharmaceutical composition or a composition-making process. A supplier selling pure rilpivirine active pharmaceutical ingredient would not necessarily practice the composition claims. A finished tablet containing rilpivirine would be more likely to implicate them.
Tablet and dosage claims
Claims 14 through 18 cover tablet forms and dosage ranges:
| Claim |
Limitation |
| 14 |
Tablet |
| 15 |
1 to 1,000 mg per unit dosage form |
| 16 |
5 to 200 mg per unit dosage form |
| 17 |
Tablet containing 1 to 1,000 mg |
| 18 |
Tablet containing 5 to 200 mg |
The commercial Edurant strength is 25 mg rilpivirine equivalent per tablet. That strength falls within both the 1-to-1,000 mg and 5-to-200 mg ranges.
These claims have limited differentiation value because they use broad dosage ranges. A 25 mg tablet would fall within the literal numerical ranges, but the claims still require the composition and tablet limitations specified elsewhere in the claim set.
What method-of-use claims does US Patent 7,125,879 contain?
Claims 13 and 19 cover treatment of HIV infection.
Claim 13: HIV treatment
Claim 13 covers administering an effective amount of a claimed compound to a subject suffering from HIV infection. The claim does not appear limited to a particular viral load, CD4 count, dosing schedule, treatment duration, or combination regimen.
Claim 19: resistant HIV-1
Claim 19 is narrower and commercially more important from a differentiation standpoint. It covers treatment of HIV-1 in subjects who have acquired resistance to known NNRTIs.
The claim requires:
- HIV-1 infection;
- Acquired resistance to prior art NNRTIs; and
- Administration of an effective amount of the claimed rilpivirine compound.
This claim reflects rilpivirine’s pharmacological positioning as an NNRTI with activity against strains resistant to certain earlier NNRTIs. It does not necessarily cover every patient receiving rilpivirine. The resistance limitation would require proof that the treated subject had acquired resistance to an applicable known NNRTI.
When did US Patent 7,125,879 lose exclusivity?
The core US patent term expired in 2021.
Exclusivity timeline
| Event |
Date |
| Priority period |
2000 |
| PCT and US filing period |
2001 |
| US patent grant |
October 24, 2006 |
| Edurant FDA approval |
May 20, 2011 |
| Core patent expiration |
May 23, 2021 |
| Potential pediatric extension |
Up to November 23, 2021, if applicable |
Patent expiration and FDA exclusivity are separate rights. The patent term is governed by the Patent Act. FDA exclusivity is governed by the Federal Food, Drug, and Cosmetic Act and may restrict approval of competing applications without extending every patent claim.
Rilpivirine’s five-year new chemical entity exclusivity associated with Edurant expired in 2016. The core composition patent remained the principal US barrier after that date until its 2021 expiration. [2]
What is the Orange Book status of rilpivirine?
Edurant was approved by FDA as rilpivirine hydrochloride tablets under NDA 201985 on May 20, 2011. FDA approved the product for use with other antiretroviral agents in adults and pediatric patients meeting the labeled criteria. [2]
The Orange Book historically listed US Patent 7,125,879 for rilpivirine products. The patent’s listed term has expired. An expired Orange Book patent does not support a current patent-based block against an ANDA applicant, although a generic applicant may still face other listed patents, regulatory exclusivity, labeling issues, or separate formulation and combination-product patents.
FDA-approved products containing rilpivirine
| Product |
Components |
Approval status |
| Edurant |
Rilpivirine |
FDA-approved |
| Complera |
Emtricitabine, rilpivirine, tenofovir disoproxil fumarate |
FDA-approved |
| Odefsey |
Emtricitabine, rilpivirine, tenofovir alafenamide |
FDA-approved |
| Juluca |
Dolutegravir, rilpivirine |
FDA-approved |
| Cabenuva |
Cabotegravir, rilpivirine extended-release injections |
FDA-approved |
The combination products have separate patent estates. A generic rilpivirine tablet does not automatically have freedom to market a fixed-dose combination or long-acting injectable product.
Which patents protect rilpivirine beyond US Patent 7,125,879?
The broader rilpivirine patent landscape has several layers.
Core compound patents
The core layer covers rilpivirine and its chemical forms. US 7,125,879 is the principal US compound patent identified with the drug.
Formulation patents
Formulation patents may cover:
- Particle-size control;
- Suspension systems;
- Solubilization or dispersion technologies;
- Oral tablet compositions;
- Extended-release injectable formulations;
- Specific excipient combinations;
- Long-acting nanosuspensions.
These patents are more relevant to Cabenuva and other depot formulations than to the basic 25 mg Edurant tablet. A company developing an oral generic would primarily assess the expired compound patent and any unexpired oral formulation patents. A company developing an injectable rilpivirine product would face a materially different patent analysis.
Method-of-use patents
Method patents can cover:
- Treatment of HIV infection;
- Treatment of NNRTI-resistant HIV-1;
- Combination treatment with other antiretrovirals;
- Long-acting dosing regimens;
- Maintenance therapy after viral suppression.
Claim 19 of US 7,125,879 is a method-of-use claim directed to NNRTI-resistant HIV-1. Later patents may target specific treatment combinations or administration schedules.
Combination-product patents
Odefsey, Complera, and Juluca each involve additional active ingredients. Their patent estates can cover:
- Specific active-ingredient combinations;
- Fixed-dose tablets;
- Pharmacokinetic combinations;
- Treatment populations;
- Dosing regimens;
- Formulation and manufacturing processes.
A generic rilpivirine product could enter without obtaining approval for these combinations, while generic competition to Juluca or Odefsey would require a separate patent and regulatory review.
Were there Paragraph IV challenges to US Patent 7,125,879?
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. Public information associated with rilpivirine does not establish a major litigated Paragraph IV challenge to US 7,125,879 comparable to the high-volume challenges seen for larger primary-care products.
The commercial pattern explains the limited litigation record. Rilpivirine is a specialized HIV product with a smaller market than many blockbuster drugs. Generic entry incentives were also affected by:
- Combination-product competition;
- Restricted HIV treatment markets;
- Existing branded alternatives;
- The need to establish bioequivalence for the relevant salt and dosage form;
- Separate patents for long-acting formulations and combination products.
The absence of a reported high-profile Paragraph IV trial does not establish validity. It indicates that the patent appears to have reached expiration without a publicly prominent invalidity decision determining the core claims.
How strong was the patent estate for rilpivirine?
Before expiration, the estate was strong at the active-ingredient level and more variable at the formulation and method levels.
| Estate layer |
Relative strength before expiration |
Reason |
| Core rilpivirine compound |
High |
Direct compound and salt coverage |
| E-isomer hydrochloride |
High |
Closely matched the marketed form |
| Tablet dosage range |
Moderate |
Broad but dependent on composition and tablet limitations |
| General HIV treatment |
Moderate |
Required proof of treatment with the claimed compound |
| NNRTI-resistant HIV-1 treatment |
Moderate to high |
Narrower clinical limitation with commercial relevance |
| Oral formulation |
Dependent on separate patents |
Risk varied by excipients and formulation design |
| Long-acting injectable |
Separate estate |
Different delivery system and manufacturing issues |
| Fixed-dose combinations |
Separate estate |
Combination-specific patents and exclusivity |
The strongest claims were claims 1, 2, 7, and 8 because they mapped closely to the active pharmaceutical ingredient and commercial hydrochloride salt. Claims 11 through 18 were easier to design around if a competing product avoided the claimed tablet or dosage limitations. Claim 19 had meaningful clinical relevance but a narrower evidentiary scope.
What generic launch risks exist after expiration?
The expiration of US 7,125,879 removes the principal composition-patent barrier to a rilpivirine hydrochloride tablet, but it does not eliminate all launch risks.
Remaining generic-entry issues
A generic developer would need to evaluate:
- Any unexpired Orange Book-listed patents for the specific product;
- FDA exclusivity associated with the relevant NDA;
- Bioequivalence to rilpivirine hydrochloride tablets;
- Labeling for HIV treatment and resistance populations;
- Salt form and polymorph identity;
- Tablet composition and excipient selection;
- Manufacturing controls for low-dose content uniformity;
- Combination-product patents;
- Patent rights covering injectable or long-acting formulations;
- Global patent rights in each launch country.
Rilpivirine has a relatively low commercial dose, 25 mg in Edurant, making content uniformity and dissolution important technical issues. Those issues may create regulatory and manufacturing barriers without creating infringement of the expired compound patent.
Which companies are associated with rilpivirine patent rights and commercialization?
Tibotec Pharmaceuticals developed rilpivirine and was associated with the original patent filings. Janssen and Johnson & Johnson later commercialized rilpivirine products.
The principal commercial rights structure is:
| Company |
Role |
| Tibotec Pharmaceuticals |
Original discovery and patent-holder organization |
| Janssen Pharmaceuticals |
US commercialization and product sponsorship |
| Johnson & Johnson |
Parent-company commercial and development organization |
| ViiV Healthcare |
Partner in the dolutegravir/rilpivirine Juluca product |
Rilpivirine was not principally commercialized through a conventional external licensing transaction comparable to some specialty pharmaceuticals. Its main commercial history reflects internal Tibotec/Janssen development and subsequent combination-product collaboration.
What is the revenue exposure associated with US Patent 7,125,879?
The patent supported a product family rather than a single product. Revenue exposure included:
- Edurant monotherapy tablets;
- Complera fixed-dose tablets;
- Odefsey fixed-dose tablets;
- Juluca fixed-dose tablets;
- Cabenuva long-acting injectable treatment.
The direct exposure to US 7,125,879 was greatest for rilpivirine-containing products using the covered active ingredient. The patent did not independently protect emtricitabine, tenofovir, dolutegravir, cabotegravir, or the full combination-product architecture.
Commercial risk therefore shifted over time. After expiration of the core rilpivirine patent, remaining value depended more heavily on combination patents, long-acting delivery patents, regulatory exclusivity, physician switching behavior, manufacturing complexity, and the patent estates for the companion drugs.
What geographic coverage does the patent provide?
US 7,125,879 provides rights only in the United States. Parallel patent families were filed in other jurisdictions, but US expiration does not determine foreign expiration.
A global launch assessment must separately review:
- European Patent Office and national European rights;
- Canada;
- Japan;
- Australia;
- China;
- India;
- Brazil;
- Other HIV-treatment markets.
Patent-term calculations, supplementary protection certificates, pediatric extensions, compulsory licensing rules, and national disclosure requirements vary by jurisdiction. The US core patent’s expiration does not establish global freedom to operate.
What manufacturing and intellectual-property barriers remain?
The expired compound patent does not remove technical barriers associated with rilpivirine manufacture.
Relevant manufacturing issues include:
- Synthesis of the diarylpyrimidine core;
- Control of the cyanoethenyl stereochemical form;
- Removal of geometric isomer impurities;
- Salt formation and solid-state characterization;
- Particle-size control;
- Tablet blend uniformity at a 25 mg dose;
- Dissolution performance;
- Stability under storage conditions;
- Injectable nanosuspension production for long-acting products.
For an oral generic, the expired composition claim materially reduces patent risk. For an injectable product, manufacturing know-how and separate formulation patents may remain more significant than the expired core compound patent.
Key Takeaways
- US Patent 7,125,879 is the core US patent associated with rilpivirine, or TMC278.
- Claims 1 and 2 cover the principal compound; claims 5 through 10 cover salts, the E-isomer, hydrochloride, and N-oxides.
- Claims 11 through 18 cover pharmaceutical compositions, tablets, and dosage ranges.
- Claim 13 covers HIV treatment; claim 19 covers HIV-1 treatment in patients resistant to known NNRTIs.
- The base US patent term expired on May 23, 2021.
- Edurant was approved by FDA in 2011, and the product was historically listed with the patent in the Orange Book.
- The patent’s core composition claims no longer provide current US exclusivity after expiration.
- Separate patents may still affect rilpivirine combinations, oral formulations, injectable formulations, and dosing regimens.
- Cabenuva, Odefsey, Complera, and Juluca require separate patent and regulatory analyses.
- Generic entry risk is now driven mainly by remaining product-specific patents, regulatory requirements, formulation know-how, and commercial economics.
FAQs
Is rilpivirine hydrochloride covered by US Patent 7,125,879?
Yes. Claims 5 through 8 specifically address addition salts and the hydrochloride salt of rilpivirine, including the E-isomer hydrochloride associated with the marketed product.
Did US Patent 7,125,879 cover Edurant tablets?
Yes. The patent includes composition and tablet claims covering a pharmaceutical composition containing rilpivirine and dosage forms within the claimed milligram ranges. Edurant contains 25 mg of rilpivirine equivalent per tablet.
Does expiration of US 7,125,879 permit generic Cabenuva?
No. Cabenuva is a long-acting injectable combination containing cabotegravir and rilpivirine. Its patent and regulatory position must be assessed separately from the expired oral rilpivirine compound patent.
Does claim 19 cover all patients receiving rilpivirine?
No. Claim 19 requires treatment of HIV-1 infection in a subject who has acquired resistance to known NNRTIs. That additional patient-status limitation narrows the claim.
Can a company launch a fixed-dose rilpivirine combination after expiration of the core patent?
Not automatically. A fixed-dose product containing rilpivirine and another antiretroviral may implicate separate combination, formulation, method-of-use, or companion-drug patents.
References
- United States Patent and Trademark Office. (2006). US Patent No. 7,125,879, Diarylpyrimidines.
- U.S. Food and Drug Administration. (2011). Edurant (rilpivirine hydrochloride) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2011). Edurant approval letter and regulatory review materials.
- Janssen Pharmaceuticals, Inc. (2024). Edurant, Odefsey, Juluca, and Cabenuva product information.
